Leadership

Our leadership team—which includes our Board of Directors and Scientific Advisory Board—is deeply committed to discovering, developing, and commercializing novel, first-in-class oral therapies that address the neuromuscular dysfunction of sleep-related breathing diseases. Members of our leadership team, driven by the aspiration to simplify and expand treatment for people living with mild, moderate, and severe OSA, have directly contributed to the foundational academic research that ultimately led to the discovery of our lead investigational candidate, AD109.

The leadership team represents and upholds the core values that drive all we do at Apnimed. We boldly challenge convention, uplift each other, and foster shared purpose and connection within our walls and beyond them, and we are passionate about our mission to create the best outcomes possible for people living with sleep-related breathing diseases.